Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 16.19M | $623.0M | 7.85% | -761.4K | 2026-06-30 |
| Deep Track Capital, LP | 9.34M | $359.0M | 4.53% | -2.19M | 2026-06-30 |
| BlackRock, Inc. | 7.18M | $276.0M | 3.48% | +606.4K | 2026-06-30 |
| Farallon Capital Management, L.L.C. | 5.80M | $223.0M | 2.81% | -- | 2026-06-30 |
| Baker Bros. Advisors LP | 5.44M | $209.0M | 2.64% | -22.7K | 2026-06-30 |
| State Street Corp | 4.62M | $177.0M | 2.24% | +79.1K | 2026-06-30 |
| Morgan Stanley | 4.53M | $174.0M | 2.20% | +658.0K | 2026-06-30 |
| TCG Crossover Management, LLC | 4.46M | $171.0M | 2.16% | -- | 2026-06-30 |
| Vanguard Portfolio Management LLC | 3.91M | $150.0M | 1.90% | +205.6K | 2026-06-30 |
| Vanguard Capital Management LLC | 3.64M | $140.0M | 1.76% | +18.6K | 2026-06-30 |
